While further studies are required to determine whether the PUM1-TRAF3 fusion is a druggable target, we successfully showed that it significantly reduces the proliferation of BTC tumor cells, elicits a reduction in p52 expression in the nucleus, and suppresses NIK accumulation, by treating cells with the NIK inhibitor B022. Here, NFKB2 is linked to neoplasm.